STOCK TITAN
  1. Home
  2. News
  3. ISPC

iSpecimen Inc - ISPC STOCK NEWS

Welcome to our dedicated news page for iSpecimen (Ticker: ISPC), a resource for investors and traders seeking the latest updates and insights on iSpecimen.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect iSpecimen's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of iSpecimen's position in the market.

News
iSpecimen Expands Provider Network to Enhance Support for Women’s Health Research
Rhea-AI Summary
iSpecimen expands provider network to advance women's health research
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.77%
Tags
none
-
News
iSpecimen Announces Organizational Changes to Enhance Operational Efficiencies and Drive Profitability
Rhea-AI Summary
iSpecimen focuses on core revenue drivers, expense reductions, and new revenue growth opportunities. Immediate headcount reductions of approximately 20% of the workforce. Monthly expenses expected to decrease by approximately 29% and 52%. Launch of virtual cancer sequencing procurement program to provide researchers with consistent access to tumor tissues. Strong demand for these samples.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.99%
Tags
none
-
News
iSpecimen Launches New Virtual Cancer Sequencing Procurement Program
Rhea-AI Summary
iSpecimen launches program providing cancer researchers with direct access to mutation-characterized tumor tissues, relieving a major bottleneck in cancer research.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.8%
Tags
none
News
iSpecimen Enhances Proprietary Marketplace Platform to Streamline Biospecimen Matchmaking for Researchers and Providers
Rhea-AI Summary
iSpecimen Inc. has enhanced its Marketplace platform to streamline biospecimen matchmaking for researchers and providers. The platform now collects and tracks over 30 unique data points, including specimen availability, patient populations, storage and shipping access, and testing capabilities. The goal is to give researchers access to the precise samples they need, while also increasing providers' return on investment and optimizing workflows.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.03%
Tags
none
-
News
iSpecimen Introduces New Marketplace Functionality to Streamline Access to Clinical Remnant Samples for Researchers
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.76%
Tags
none
-
News
iSpecimen Reports Second Quarter 2023 Financial and Operating Results
Rhea-AI Summary
iSpecimen Inc. reported financial and operating results for Q2 2023. While revenue decreased by 31% compared to Q2 2022, the company implemented new initiatives to increase order fulfillment and witnessed an increase in backlog. The company aims to create an expansive global biospecimen supply chain technology platform and marketplace. Q2 2023 highlights include 7.5% increase in unique supplier organizations, 22% increase in unique customer organizations, and 24% increase in registered research and supplier users.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.93%
Tags
earnings
News
iSpecimen to Report Second Quarter 2023 Results on August 2, 2023
Rhea-AI Summary
iSpecimen Inc. will report its financial results for Q2 2023 on August 2, 2023. The company is an online global marketplace connecting scientists with healthcare specimen providers. The conference call and audio webcast will feature remarks by CEO Tracy Curley. A replay of the call will be available until August 16, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.45%
Tags
conferences earnings
-
News
Thirteen New Biospecimen Suppliers Added to iSpecimen’s Proprietary Provider Network
Rhea-AI Summary
iSpecimen Inc. has added thirteen new biospecimen suppliers to its proprietary Marketplace®, expanding the breadth and depth of biospecimen offerings for researchers. The expanded network provides greater access to human biosamples in various disease categories. The new suppliers offer a wide range of sample types, including banked and prospectively collected samples. Notably, one supplier offers access to over 640,000 patients across five sites, while another specializes in isolated immune cells and banked antigen-specific T cells. Additionally, iSpecimen added a supplier focused on frozen clinical-grade cord blood and another exclusively sourcing biospecimens from African patient pools to promote diversity in research.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.26%
Tags
none
-
News
iSpecimen to Participate in Maxim’s Healthcare IT Virtual Conference on June 1, 2023
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.03%
Tags
conferences
News
iSpecimen Reports First Quarter 2023 Results
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.45%
Tags
earnings
Stock ISPC logo
iSpecimen Inc

Nasdaq:ISPC

ISPC Rankings

N/A Ranked by Market Cap
N/A Ranked by Stock Gains
N/A Ranked by Dividends

ISPC Stock Data

2.06M
6.90M
33.77%
4.31%
5.06%
Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology)
Professional, Scientific, and Technical Services
Link
United States
Lexington

About ISPC

headquartered in lexington, ma, ispecimen is the marketplace for human biospecimens, providing researchers with the specimens they need from the patients they want. the privately held company has developed the ispecimen marketplace, an online platform connecting healthcare organizations that have access to patients and specimens with the scientists who need them. proprietary, cloud-based technology enables researchers to intuitively search for specimens and patients across a federated partner network of hospitals, labs, biobanks, blood centers, and other healthcare organizations. researchers easily and compliantly gain access to specimens to drive scientific discovery. partner sites gain an opportunity to contribute to biomedical discovery as well as their bottom line. and ultimately, healthcare advances for all.